Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

Bioactive Glass (S53P4) as Bone Graft Substitute in Operative Treatment of Depressed Lateral Condyle Fractures, Benign Bone Tumour Cavities and in Spinal Fusion - a 10 Years Follow-up and Bone Density Study.

The main aim is to evaluate the long-term safety and bone healing in the operated area and to compare bioactive glass granules with autogenous bone as a filler material.

Inclusion Criteria:

• Written informed consent obtained; Participation of previous clinical investigation with bioactive glass

Exclusion Criteria:

• The subject is unlikely to adhere to study procedures
• Concurrent disease or condition that in the opinion of the investigator is contraindicating participation
• Simultaneous participation in another medical device or investigational drug trial